Business Wire

ThreatNG Security Offers Free Access to Their Groundbreaking Security Platform for Organizations to Assess Cloud and SaaS Vulnerabilities

28.2.2023 17:00:00 EET | Business Wire | Press release

Share

ThreatNG, a cybersecurity company dedicated to empowering organizations of all sizes to manage their external attack surface and digital risks, has announced the release of its agentless Cloud and SaaS Exposure Assessment Module. The company also announced free access to organizations to this groundbreaking platform to assess their external risk for a limited time.

The ThreatNG “Cloud and SaaS Exposure” Module supports the following vendors and technology categories:

- Amazon Web Services (AWS)
- Microsoft Azure
- Google Cloud Platform (GCP)
- Analytics
- Business Intelligence (BI)
- Customer Relationship Management (CRM)
- File Sharing
- Human Resources
- Security
- Video Telephony

ThreatNG continues to redefine External Attack Surface Management (EASM), Digital Risk Protection, and Security Ratings by announcing the availability of its Agentless Cloud and SaaS Exposure Assessment Module. Requiring only a domain and organization name, ThreatNG users can perform Outside-In Discovery, Assessment, Reporting, and Monitoring of their Cloud and SaaS Footprint, uncover Exposed Open Cloud Buckets, bring to light Unsanctioned Implementations (Shadow IT), and call to attention Brand Impersonations (Cybersquats) without using agents, credentials, API connections, browser plugins, and any other means that require prior knowledge.

ThreatNG further empowers its users by providing a differentiated, unmatched, and holistic approach by extending discovery and assessment of all Internet-exposed online applications, repositories, APIs, platform-as-a-service (PaaS), infrastructure-as-a-service (IaaS), and vendor technologies interconnected with Cloud and SaaS implementations.

“As more critical data and functions are migrating to the cloud, it becomes much more important for organizations to have visibility of all their digital assets exposed to the public and address all potential risks and threats. Our Cloud and SaaS Exposure module empower users with a proactive outside-in perspective,” said Eric Gonzales, founder of ThreatNG. “We are so confident in our technology’s capability that we are willing to provide organizations of all sizes with a free discovery and risk assessment of their Cloud and SaaS environments.”

To learn more about ThreatNG and its Cloud and SaaS Exposure Assessment capabilities, visit the company’s website, www.threatngsecurity.com/cloudexposure.

Cloud and SaaS Environments are continuously evolving. With new instances appearing, this constant change makes it challenging to keep an accurate inventory of sanctioned implementations and maintain good cyber hygiene overall. This growing Cloud and SaaS sprawl feeds into the ever-increasing problem of Shadow IT (Unsanctioned Implementations) and Cybersquats (Brand Impersonations). This uncontrollable sprawl has also led to increased security risks and exposures, a growth in phishing attacks abusing SaaS platforms, and cloud assets compromised more than on-premise assets (Verizon 2022 Data Breach Investigations Report).

Cloud and SaaS Impersonations (Cybersquats) and Exposed Data within Open Cloud Buckets are growing problems with organizations of all sizes and their Third Parties. Still, they are out of scope within most External Attack Surface Management (EASM), Digital Risk Protection, and Security Rating Services. ThreatNG unites these solution capabilities and empowers users to seamlessly bring Cloud and SaaS into the fold of Asset Inventory, Security & Governance, Subsidiary Security Monitoring, Third-Party Security Assessments, and Brand Protection through their innovative external discovery and assessment requiring only a domain and organization name.

Support for all of the above is available today and accompanied by all of the following investigation modules provided to all ThreatNG users:

  • Domain Intelligence
  • Technology Stack
  • Sensitive Code Exposure
  • Online Sharing Exposure
  • Search Engine Exploitation
  • Sentiment and Financials
  • Archived Web Pages
  • Social Media
  • Dark Web

Contact ThreatNG Security today for a Free 30-Day Evaluation of their Cloud and SaaS Exposure Assessment Module.

About ThreatNG

ThreatNG is redefining external attack surface management (EASM), digital risk protection, and security ratings with a platform of unmatched breadth, depth, and capabilities in managing technical and business threats across the dark, deep, and open web. Living up to the company mantra (“Security Centric; Not Exclusive”), ThreatNG provides a configurable solution to target, discover, and assess digital assets across a definable ecosystem of organizations, subsidiaries, partners, third parties, supply chains, and customers. Bolstered and maintained by the open source intelligence (OSINT) experts at DarcSight Labs, ThreatNG empowers organizations of all types and sizes to uncover, understand, and manage their external digital threats.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Erin Price
Email: erin@threatngsecurity.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye